WHO ICTRP trial
Phase ? Study to Evaluate the Efficacy and Safety of Regdanvimab for Patients…
KCT0006254 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0006254 |
|---|---|
| Public title | Phase ? Study to Evaluate the Efficacy and Safety of Regdanvimab for Patients with Mild to Moderate Symptoms of Severe Acute Respiratory Syndrome Coronavirus 2 Infection |
| Scientific title | Phase ? Study to Evaluate the Efficacy and Safety of Regdanvimab for Patients with Mild to Moderate Symptoms of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection |
| Primary sponsor | Incheon Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Codes for special purposes |
| Interventions | Drug : 40 mg/kg of Regdanvimab (960 mg/16 mL) administered by intravenous (IV) for 90 minutes (with a margin of error of ±15 minutes). |
| Registration date | Jun 14, 2021 |
| Target size | 20 |
| Registry page | cris.nih.go.kr |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: